DENVER, Jan. 29 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that it will report 2003 fourth
quarter and year-end results on Wednesday, February 18, 2004, before the U.S.
financial markets open.
J. William Freytag, President and CEO, and other members of Myogen's
senior management will then provide a company update and discuss results via
webcast and conference call on Wednesday, February 18, 2004 at 4:15pm Eastern.
To access the live webcast, please log on to the company's website at
http://www.myogen.com and go to the Investor Relations section. Alternatively,
callers may participate in the conference call by dialing 800-218-0713
(domestic) or 303-262-2141 (international). Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Friday, February 27, 2004. Callers can access
the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international).
The passcode is 568765#.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of chronic heart failure, ambrisentan for the treatment of
pulmonary arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com .
Safe Harbor Statement
The 2003 results press release and conference call will contain
forward-looking statements that involve significant risks and uncertainties,
including those discussed in the release, those to be discussed in the
conference call and others that can be found in the "Risk Factors" section of
Myogen's Prospectus filed on October 30, 2003 and in our Form 10-Q filed on
December 4, 2003. Myogen does not undertake any obligation to update any
forward-looking statements contained in the results press release or the
anticipated conference call as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the conference
call. No forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.
For further information, please contact Derek K. Cole, Director, Investor
Relations of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
